Milnacipran in the treatment of bulimia nervosa: A report of 16 cases

European Neuropsychopharmacology

Volumn 13, Issue 2, 2003, Pages 73-79

  El Giamal, Nadia ^a   De Zwaan, Martina ^a   Bailer, Ursula ^a   Strnad, Alexandra ^a   Schüssler, Petra ^a   Kasper, Siegfried ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Bulimia nervosa; Milnacipran; Serotonin and noradrenaline reuptake inhibitor; Treatment

Indexed keywords

MILNACIPRAN; NORADRENALIN UPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR;

ADULT; ARTICLE; BECK DEPRESSION INVENTORY; BINGE EATING DISORDER; BULIMIA; CLINICAL ARTICLE; DEPRESSION; DRUG ERUPTION; DRUG SURVEILLANCE PROGRAM; DYSURIA; FEMALE; HAMILTON SCALE; HEADACHE; HEART PALPITATION; HUMAN; HYPERHIDROSIS; NAUSEA; OUTPATIENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; SLEEP DISORDER; TREATMENT OUTCOME; VOMITING; XEROSTOMIA;

EID: 0037338299     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-977X(02)00126-8     Document Type: Article

References (40)

1. Agras W., Dorian B., Kirkley B. Imipramine in the treatment of bulimia: a double-blind controlled study. Int. J. Eat. Disord. 6:1987;29-38.
2. Agras W., Rossiter E., Arnow B., Schneider J., Telch C., Raeburn S., Bruce B., Perl M., Koran L. Pharmacologic and cognitive-behavioral treatment for bulimia nervosa: a controlled comparison. Am. J. Psychiatry. 149:1992;82-87.
3. 4th Edition Diagnostic and Statistical Manual of Mental Disorders. 1995;American Psychiatric Association, Washington, DC.
4. Bacaltchuk J., Hay P., Mari J.J. Antidepressants versus placebo for the treatment of bulimia nervosa: a systematic review. Aust. N.Z. J. Psychiatry. 34:2000;310-317.
5. Beck A.T., Ward C.H., Mendelson M., Mock J., Erbaugh J. An inventory for measuring depression. Arch. Gen. Psychiatry. 4:1961;53-63.
6. Barlow J., Blouin J., Blouin A., Perez E. Treatment of bulimia with desipramine: a double-blind crossover study. Can. J. Psychiatry. 33:1988;129-133.
7. Blouin A., Blouin J., Perez E., Bushnik T., Zuro C., Mulder E. Treatment of bulimia with fenfluramine and desipramine. J. Clin. Psychopharmacol. 8:1988;261-269.
8. Brewerton T.D., Mueller E.A., Lesem M.D., Brandt H.A., Quearry B., George D.T., Murphy D.L., Jimerson D.C. Neuroendocrine responses to m-chlorophenylpiperazine and L-tryptophan in bulimia. Arch. Gen. Psychiatry. 49:1992;852-861.
9. Briley M. Milnacipran, a well-tolerated specific serotonin and norepinephrine reuptake inhibiting antidepressant. CNS Drug Rev. 4:1998;137-148.
10. El-Giamal N., de Zwaan M., Bailer U., Lennkh C., Schüssler P., Strnad A., Kasper S. Reboxetine in the treatment of bulimia nervosa: a report of seven cases. Int. Clin. Psychopharmacol. 15:2000;351-356.
11. Fichter M. Die medikamentöse Behandlung von Anorexia nervosa und Bulimia nervosa. Nervenarzt. 64:1993;21-35.
12. Fluoxetine in the treatment of bulimia nervosa. Arch. Gen. Psychiatry. 49:1992;139-147.
13. Goldbloom D.S., Garfinkel P.E., Katz R., Brown G. The hormonal response to intravenous 5-hydroxytryptophan in bulimia nervosa. Psychosom. Med. 52:1990;225-226.
14. Goldstein D., Wilson M., Thompson V., Potvin J., Rampey A. Long-term fluoxetine treatment of bulimia nervosa. Br. J. Psychiatry. 166:1995;660-666.
15. Hamilton W. Development of a rating scale for primary depressive illness. Br. J. Soc. Clin. Psychol. 6:1967;278-296.
16. Hughes P., Wells L., Cunningham C., Ilstrup D. Treating bulimia with desipramine. Arch. Gen. Psychiatry. 43:1986;182-186.
17. Jimerson D.C., Wolfe B.E., Metzger E.D., Finkelstein D.M., Cooper T.B., Levine J.M. Decreased serotonin function in bulimia nervosa. Arch. Gen. Psychiatry. 54:1997;529-534.
18. Kasper S. The place of milnacipran in the treatment of depression. Hum. Psychopharmacol. Clin. Exp. 12:1997;S135-S141.
19. Kasper S., Pletan Y., Solles A., Tournoux A. Comparative studies with milnacipran and tricyclic antidepressants in the treatment of patients with major depression: a summary of clinical results. Int. Clin. Psychopharmacol. 11:(Suppl. 4):1996;35-39.
20. Kaye W.H., Greeno C.G., Moss H., Fernstrom J., Fernstrom M., Lilenfeld L.R., Weltzin T.E., Mann J.J. Alterations in serotonin activity and psychiatric symptoms after recovery from bulimia nervosa. Arch. Gen. Psychiatry. 55:1998;927-935.
21. Kaye W., Ballenger J., Lydiard B., Stuart G., Laraia M., O'Neil P., Fossey M., Stevens V., Lesser S., Hsu G. CSF monoamine levels in normal weight bulimia: evidence for abnormal noradrenergic activity. Am. J. Psychiatry. 147:1990;225-229.
22. Leitenberg H., Rosen J., Vara L., Detzer M., Srebnik D. Comparison of cognitive-behavior therapy and desipramine in the treatment of bulimia nervosa. Behav. Res. Ther. 32:1994;37-45.
23. Lennkh C., de Zwaan M., Kasper S. New aspects of diagnosis and pharmacotherapy of eating disorders. Int. J. Psychiatr. Clin. Pract. 1:1997;21-35.
24. Levitan R.D., Kaplan A.S., Joffe R.T., Levitt A.J., Brown G.M. Hormonal and subjective responses to intravenous meta-chlorphenylpiperazine in bulimia nervosa. Arch. Gen. Psychiatry. 54:1997;521-527.
25. McBride P.A., Anderson G.M., Khait V.D., Sunday S.R., Halmi K.A. Serotonergic responsivity in eating disorders. Psychopharmacol. Bull. 27:1991;365-372.
26. Mitchell J.E., Hatsukami D., Eckert E.D., Pyle R.L. Eating disorders questionnaire. Psychopharmacol. Bull. 21:1985;1025-1043.
27. Monteleone P., Brambilla F., Bortolotti F., Ferraro C., Maj M. Plasma prolactin response to D-fenfluramine is blunted in bulimic patients with frequent binge episodes. Psychol. Med. 28:1998;975-983.
28. Montgomery S., Prost J., Solles A., Briley M. Efficacy and tolerability of milnacipran: an overview. Int. Clin. Psychopharmacol. 11:1996;47-51.
29. CGI. Clinical Global Impressions. Guy W. ECDEU Assessment Manual for Psychopharmacology, Revised Edition. 1976;217-222 NIMH, Rockville, MD.
30. Oldman A., Walsh A., Salkovskis P., Fairburn C.G., Cowen P.J. Biochemical and behavioural effects of acute tryptophan depletion in abstinent bulimic subjects: a pilot study. Psychol. Med. 25:1995;995-1001.
31. Pirke K.M. Central and peripheral noradrenalin regulation in eating disorders. Psychiatry Res. 62:1996;43-49.
32. Smith K.A., Fairburn C.G., Cowen P.J. Symptomatic relapse in bulimia nervosa following acute tryptophan depletion. Arch. Gen. Psychiatry. 56:1999;171-176.
33. 123]-β-CIT and single photon emission computed tomography reveal reduced brain serotonin transporter availability in bulimia nervosa. Biol. Psychiatry. 49:2001;326-332.
34. Thiel A., Jacobi C., Horstmann S., Paul T., Nutzinger D., Schüßler G. Eine deutschsprachige Version des Eating Disorder Inventory EDI-2. P.P.m.P. 47:1997;365-376.
35. Walsh T., Hadigan C., Devlin M., Gladis M., Roose S. Long-term outcome of antidepressant treatment for bulimia nervosa. Am. J. Psychiatry. 148:1991;1206-1212.
36. Walsh B., Wilson T., Loeb K., Devlin M., Pike K., Roose S., Fleiss J., Waternaux C. Medication and psychotherapy in the treatment of bulimia nervosa. Am. J. Psychiatry. 154:1997;523-531.
37. Weltzin T.E., Fernstrom J.D., McConaha C., Kaye W.H. Acute tryptophan depletion in bulima: effects on large neutral amino acids. Biol. Psychiatry. 35:1994;388-397.
38. Weltzin T.E., Fernstrom M.H., Fernstrom J.D., Neuberger S.K., Kaye W.H. Acute tryptophan depletion and increased food intake and irritability in bulimia nervosa. Am. J. Psychiatry. 152:1995;1668-1671.
39. Wittchen H.-U., Wundrich U., Gruschwitz S., Zaudig M. SKID-I Strukturiertes Klinisches Interview für DSM-IV. Achse I: Psychische Störungen. 1997;Hogrefe Verlag für Psychologie, Göttingen.
40. Wolfe B.E., Metzger E.D., Levine J.M., Finkelstein D.M., Cooper T.B., Jimerson D.C. Serotonin function following remission from bulimia nervosa. Neuropsychopharmacology. 22:2000;257-263.